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— causes and symptoms of cardiovascular damage
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Since the introduction of new drugs, (commonly referred to as ‘Molecular Target Therapies’), into oncological clinical 
practice both the number of objective indicators/endpoints of achieved treatment response and cancer survival 
duration have increased. Nevertheless, the risk of cardiovascular complications has also risen. Optimistic reports 
on the relatively low cardiotoxicity of these drugs have been verified through experience. Routine clinical practice 
has witnessed growing numbers of new drug groups that have different molecular target points and also a varied 
cardiotoxicity. 
This paper presents the most important cardiovascular complications associated with the use of molecularly targeted 
drugs and includes their mechanisms of development.
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Introduction
Administering molecularly targeted systemic cancer 
treatment represents a new and valued benefit in oncology. 
An important element to this approach is recognising that 
certain genetic abnormalities are associated with malignant 
transformation, growth factors and their receptors. The 
proliferation and differentiation of malignant cells caused 
by the triggering of the ‘molecular pathway’ arises from 
activation of membrane receptors. When modified, these 
molecular mechanisms may allow prolonged progression-
-free survival and also in some cancer patients, their overall 
survival. Nevertheless, despite the optimistic toxicity profiles 
reported initially, it became apparent very soon that many 
were associated with adverse reactions (including signifi-
cant cardiac toxicity) making their withdrawal necessary 
or even resignation from the anti-cancer treatment [1]. It 
must of course be remembered that such drugs are often 
given to patients, who had been previously treated with 
conventional chemotherapy and which had also affected 
their cardiovascular system [2]. Furthermore, a significant 
number of cancer patients suffered from concomitant di-
seases. Data from the National Cancer Registry shows that 
cancer develops over the age of 60 years in 70% of men 
and in 60% of women, and is most common in the eighth 
decade of life; this being very well illustrated in prostate 
cancer cases [3]. In some clinical settings, just a solitary 
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characteristic of the tumour (for instance its localisation) 
may cause cardiovascular disturbances. 
Within this context tumours of the heart are of minor 
importance; both primary and secondary. The former are 
very rare (accounting for about 0.02%) and are usually 
present as sarcomas and lymphomas [4], whilst metastatic 
lesions are more common (accounting for approximately 
21% cases; mainly including the pericardium by direct 
infiltration and less commonly, through metastasising via 
blood vessels or lymphatic routes). Clinical manifestations 
of secondary heart tumours are relatively late and are 
often accidentally recognised during imaging diagnostics, 
unfortunately, usually when vital structures of the heart 
have been affected [5].
The key issue underlying molecular target therapy is 
to block signal transfer which, in turn, adversely affects 
cellular division. This is usually achieved either by inac-
tivating the ligand or blocking the receptor by specific 
antibody binding, blocking auto-phosphorylation or in-
hibiting the signalling of intracellular pathways. Cell cycle 
inhibitors and proteasome inhibitors may also be used. 
The mechanisms listed above, ie. signal pathways and/or 
kinase targets are also present within normal structures 
of the heart and/or the vascular system and therefore it is 
impossible to avoid targeted drugs interfering with healthy 
cardiomyocytes, that affect the function and the survival 
of myocardial cells [6].
Cardiotoxic mechanisms of molecular target 
therapy
The working experience of molecular target therapy 
acquired over the last few years has allowed two types of 
cardiovascular toxicity mechanisms to become identified:
1. Toxicity associated with specific mechanisms of action, 
ie. associated with the activation of an identical target 
point within the cardiomyocyte (e.g. kinase or recep-
tors).
2. Toxicity associated with indirect or direct inhibition of 
other signalling pathways which, in effect, causes symp-
toms of cardiotoxicity (e.g. the affinity of sunitinib to 
block serotonin alpha and beta adrenergic receptors, 
the potassium channel protein receptor (hERG) and 
the Purkinje fibres, which is not observed in the case of 
sorafenib, which blocks only the hERG receptor protein 
and the Purkinje fibres) [7]. 
Table I shows the most common kinases which act as 
therapeutic targets for treating cancer and their potential 
effect on the cardiovascular system [8]. At present it is im-
possible to predict all potential forms of cardiotoxicity for 
molecular target therapy drugs because of the complicated 
nature of molecular targets. The vast majority of these drugs 
have multikinase effects and are characterised by different 
binding sites within the cardiomyocytes 
Cardiovascular disturbances
Hypertension
One of the more common and critical clinical complica-
tions is arterial hypertension. It is usually associated whene-
ver tyrosine kinase inhibitors (TKI) or anti-angiogenic drugs 
are given, such as bevacizumab. Among these drugs are also 
sunitinib, sorafenib and pazopanib. Their molecular action 
is based on blocking the internal domain of the vascular 
endothelial growth factor receptor (VEGFR). Bevacizumab 
has a slightly different mechanism of action, as it binds 
directly to the vascular endothelial growth factor (VEGF). 
TKIs decrease the production of nitric oxide and thereby 
increase vascular resistance and blood flow deficits within 
capillaries. This may either cause arterial hypertension or 
exacerbate any pre-existing condition [9]. Murine studies 
have shown that mechanical factors are not important for 
inducing changes within large blood vessels, however the 
decrease in afterload brought on by TKIs directly affects the 
end-systolic resistance and eventually, the systolic function 
of the heart. Thus it can be ruled out that administering TKIs 
significantly decreases the ‘functional’ density of capillaries. 
Developing hypertension is also likely to be associated 
with renal changes. Animal studies have shown lesions 
within glomerular vessels, microangiopathic thrombosis, 
proliferation of the glomerular mesangium and excessi-
ve generation of fibrin. Normally, the activation of type 
2 VEGFR activates phosphoinositide 3-kinase (PI3K)-AKT) 
and induces phosphorylation and activation of endothelial 
nitric oxides synthesis. This causes a secondary increase in 
guanylate cyclase activity and due to smooth muscle rela-
xation, blood vessels then dilate. During the production of 
nitric oxide, endothelin synthesis increases which causes 
vascular obturation. Unfortunately, the factor responsible 
for the endothelin synthesis increase remains unknown [10].
Most researchers agree that it is difficult to assess the 
number of patients with hypertension caused by TKI-treat-
ment. One reason being that there are a number of defini-
tions of hypertension applied according to the purposes 
of clinical trials. Also its measurement methods vary. The 
incidence of hypertension depends upon the type of drug. 
It is estimated that for all patients treated with TKIs, hyper-
tension develops in 15% to 60% cases and is more serious 
as regards to systolic hypertension. In the instance of beva-
cizumab, arterial hypertension is observed in some 20–30% 
cases (of whom in 11–16% cases it was observed for the 
first time). Severe hypertension is found in 8% cases, while 
hypertensive crisis in as many as 1% of subjects [11, 12]. Chu 
et al. have shown arterial pressure to be 150/100 mmHg or 
higher in 47% of patients during sunitinib therapy [13]. In 
a meta-analysis designed to assess the risk of hypertension 
in approximately 4600 patients treated for renal cancer with 
sorafenib, Wu reported grade 3 and 4 hypertension in 23% 
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and 6% of subjects, respectively. The total risk of developing 
hypertension for sorafenib therapy was 6.11, p < 0.001 [14]. 
Another meta-analysis on 5000 patients with gastrointesti-
nal stromal tumours (GIST), demonstrated that the risk of 
developing hypertension was 22.72, p < 0.001 [15].
Many workers stress that during TKIs administration, 
the rise in blood pressure may be rapid; especially in the 
case of sunitinib and sorafenib. This concerns patients who 
have not been previously treated for hypertension and may 
lead to a hypertensive crisis.
Table I. The most common kinases and their potential effects on the cardiovascular system
Kinase Role of kinase in the cardiovascular system
RAF1/ BRAF Anti-apoptotic action, maintains the function of the left ventricle under increase load (stress)
PI3K (p110a) Physiologic heart growth, affects cardiomyocyte survival
PI3K (p110y) Regulation of contractility and pathological hypertrophy 
PDK1 Affects cardiomyocyte survival and beta-adrenergic response
Akt 1, 2 or 3 Regulation of cardiomyocyte survival, growth and metabolism
mTOR Regulation of protein synthesis, inhibition causes energy preservation under duress; regulation of 
protein synthesis; inhibition leads to energy saving under stress, regulation of Akt (mTORC2) activation 
process
AMPK Supervision of energetic stress, mTOR1 inhibition while maintaining energy reserves 
GSK3 a/b mTORC1 inhibition (together with AMPK), GSKbeta deletion acts protectively in postinfarct remodelling; 
GSKalfa deletion causes cardiac insufficiency under stress
CDKs CDK2 inhibition limits heart damage in the course of ischemia-reperfusion acting through 
retinoblastomy protein
Aurora Regulator of phase M of the cellular cycle
PLKs Plk1 is involved in Cdc2 activation, chromosome segregation, centrosome maturation, forming of the 
spindle apparatus and cytokines 
PDGFR Participates in angiogenesis and in cardiac response to pressure stress (beta isoform)
VEGFR  Participates in angiogenesis and in cardiac response to pressure stress (antihypertensive effect)
EGFR (ErbB1) Preserving function of the; left ventricle under prolonged katecholamine stimulation; mediating the 
signaling pathway stimulating cell survival
ERBB2 ERBB4 Influences the survival and homeostasis of cardiomyocytes and maintains function of left ventricle
Kit Promotion of progenital cells in the heart and differentiation differentiation of immature 
cardiomyocytes, direction towards post-ischaemic sites, promoting repair
Abl/ARG Maintenance of homeostasi, in rofents treated with imatinib left ventricular dysfunction is observed
JAK2 Together with STAT3 act protectively in many pathologic situations
FAK Activation decreases heart hypertrophy and fibrosis
DMPK Type 1 myotonic dystrophy is brought on by additive repetitions of the 3’UTR regioon of the DMPK 
kinase
LTK Activation causes hypertrophy and degeneration of cardiomyocytes
ROCK Activation of fibrosis and apoptosis under hypertensive stress 
LKB1 Activation of AMPK which is proangiogenic within the heart
LDB3, ZASP and/or Cypher Induction of ZASP mutations associated with skeletal muscle myopathies
ERK 1/2 Promotion of cardiomyocyte survival, ability to modulate physiologic (but not pathologic) hypertrophy
PKC alfa Destructive influence on the heart under hypertensive stress
cGMP-dependent PK One of the four main kinases influencing cardiac failure; activated by PDE5 receptors; inhibits apoptosis, 
hypertrophy and beta-adrenergic response
PIM kinase Influences the survival of cardiomyocytes (activated by Akt, regylated at the gene expression level)
CAMKII Main kinase in cardiac failure; influences heart hypertrophy; promotes decompensation under 
hypertensive stress
GRK2 and/or GRK5 Decrease in beta-adrenergic signalling through beta-arrestin recruitment
ASK1 Promotes pathologic hypertrophy and remodelling. Pro-apoptotic
PTEN phosphatase Inhibition of hypertrophy, decrease in cardiomyocyte survival under stress; PI3K antagonist
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Prolonged QT interval
The QT interval represents the time of ventricular re-
polarisation. Its length may be affected by many factors 
(e.g. age, autonomic stress, electrolyte levels, drugs or even 
the time of day). QT interval duration depends upon heart 
rhythm; during bradycardia it is long, in tachycardia it shor-
tens. Measuring the QT interval is possible using a standard 
12-channel ECG. In clinical practice, a correction of the QT 
interval is performed based upon heart rate, and a corrected 
value (QTc) is given.
Clinical symptoms of prolonged QT may cause syncope 
or a dangerous form of arrhythmia known as torsade de po-
intes which may cause ventricular fibrillation and eventually 
death. Many drugs administered as targeted therapy may 
prolong QT. Those include TKIs, histone deacetylase inhibi-
tors, SRC/ABL inhibitors, FTpase, protein-Ckinase inhibitors, 
serine/threonine kinase protein-specific BRAF inhibitors and 
even inhibitors (blockers) of the type 3 serotonin receptor 
[12, 16, 17].
Prolonged QT interval — tyrosine kinase inhibitors
In both preclinical and phase I trials of sunitinib in pa-
tients with solid tumours, prolonged repolarisation of the 
ventricular functional potential has been observed as re-
presented by prolonged QT in a standard ECG. Changes 
in the QT interval of more than 60 ms (as compared to the 
initial values) were observed in 5% of the 84 subjects who 
had entered the study [18]. In a clinical trial involving 24 pa-
tients aged 24–87 years, the longest QT interval was seen 
on day 3, 24 hours after administering the drug (intended 
initial dose of 50 mg). This abnormality was not associated 
with any clinical problems. In none of the patients was the 
QT longer than > 500 ms [19]. It is important that sunitinib 
has a binding affinity to 5HT2a serotonin receptors, alpha 
and beta adrenergic receptors, hERG receptor protein and 
Purkinje fibres; blocking them all, which may affect repola-
risation. Besides, electron microscopy investigations have 
shown both the presence of lesions and the activation of 
degenerative processes, particularly within the mitochon-
dria as well as a significant decrease in the concentration of 
adenosine triphosphate (ATP) in the sunitinib and sorafenib 
groups [20].
Wandetanib, a tyrosine kinase inhibitor administered 
for treating medullary thyroid cancer in patients with the 
RETgene mutation, may significantly prolong ventricular 
repolarisation. A probable mechanism causing repolarisa-
tion disorders is interaction with ferrum channels within the 
heart. During a phase 1 study, QTc was prolonged in at least 
10% of subjects; however this had no clinical implications 
and did not affect the course of drug administration [21]. 
In a phase II study of patients with breast cancer in whom 
wandetanib was administered 100 mg per day together 
with docetaxel, QTc was prolonged in almost 5% of patients 
compared with the group receiving wandetanib 300 mg per 
day with docetaxel, in whom prolonged QTc was observed 
in as many as 11% of subjects. 
QTc prolongation was not observed in patients rece-
iving docetaxel as monotherapy [22]. In a clinical study of 
wandetanib administered for non-small cell lung cancer, 
QTc was prolonged in 15% cases as compared to the non-
-wandetanib controls [23].
In a phase II trial of wandetanib on plasmocytoma pa-
tients there was also no QTc prolongation [24]. In another 
phase II wandetanib study on skin melanoma, it was found 
that during the first 6 months of treatment as many as 90 
out of 132 patients had a QTc prolonged by 15.1 ms (in 2 
patients, QTc exceeded 500 ms, and in one case it reached 
60 ms compared to the initial value) [25].
In view of such findings, it must be remembered that 
the cardiotoxicity seen for this group of drugs is probably 
triggered by a different mechanism and may be associated 
with a mitochondrial effect; it also arises from receptors 
being blocked to various extents within the cardiomyocytes. 
This might be the underlying issue responsible for the varied 
cardiotoxicity of TKIs.
Prolonged QT interval — histone deacetylase 
inhibitors
Deacetylases are regulatory proteins affecting the 
expression of genes dependent upon the presence of acetyl 
groups within histones. In many malignancies, acetylation 
abnormalities have been observed and this is the rationale 
behind attempts to apply these type of drugs for anticancer 
treatment [26].
Vorinostat and romidepsin have recieved FDA appro-
val in the treatment of T-cell lymphoma of the skin, while 
the Committee for Medicinal Products for Human Use 
(CMHP) issued a negative opinion for romidepsin, stating 
that any clinical benefits have not been analysed (inclu-
ding longer overall survival). In the case of vorinostat, 
the submission for CMHP opinion had been withdrawn. 
In Europe therefore, histone deacetylase inhibitors are 
only administered in the course of clinical trials. Most of 
the data regarding their effects on the QT interval shows, 
that it is reversible and, usually of short duration. For the 
majority of patients, no symptomatic arrhythmias have 
been observed [12, 26]. 
Prolonged QT interval — SRC/ABL inhibitors
Common SRC/ABL inhibitors include nilotinib and da-
satinib which are widely used in routine clinical practice.
Dasatinib is used for treating chronic myelogenous 
leukaemia (CML) during the chronic phase in patients 
with the newly diagnosed disease who present with the 
Philadelphia chromosome (Ph+) as well as in cases of acute 
lymphoblastic leukaemia with Ph(+). In a phase II study on 
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467 patients, the median QTc prolongation was between 
3 and 6 msec and in 64 patients the QTc was 60 ms longer 
as compared to initial values whilst in 3 patients the QTc 
was prolonged over 500 msec; this study demonstrating 
that exclusion criteria be applied also to patients with 
concomitant cardiovascular diseases. Thus, there seems 
to be a rationale behind the clinical observation that the 
hERG receptor within the heart is blocked 100 times less 
when compared to nilotinib [27].
Nilotinib may cause QT prolongation. In a clinical trial 
on patients resistant to imatinib, 4% of subjects presen-
ted with a QT pronged by 60 ms compared to baseline 
values. No prolongations over 500 ms were observed. 
Sudden death was observed in 0.6% cases and it was 
impossible to tell whether they were not associated with 
abnormal ventricular repolarisation [28, 29]. It has been 
noted that other drugs which damage blood vessels, e.g. 
FTpase inhibitors and protein C kinase inhibitors (which 
are currently undergoing phase I trials), may potentially 
also prolong QTc [30].
Cardiac ischemia
Bevacizumab combined with standard chemotherapy 
may increase the number of emboli within the cardiovascu-
lar system and within the central nervous system. In a re-
trospective analysis, Scappaticci et al. showed a statistically 
significant risk of thromboembolism with combined therapy 
(standard + bevacizumab). The absolute risk of thrombo-
embolic episodes reached 5.5 per 100 patient-years in the 
combined treatment group compared to 3.1 in the group 
receiving standard chemotherapy only. Risk factors included 
age over 65 yrs and previous thromboembolic episodes [31]. 
Schimdinger reported thrombo-embolic incidents in 24% 
of patients treated with sunitinib [18]. In 17.6% of patients 
treated with sunitinib, a significant increase in the troponin 
level has been reported [13].
Dysfunction of the left ventricle
Different mechanisms underlie left ventricle dysfunction 
resulting from molecular target therapy. The best known is 
that associated with trastuzumab.
HER2 protein (ErB2) belongs to the family of epidermal 
growth factor receptors; EGFR. It is found on the malignant 
cells in some 20% of breast cancer patients. The protein 
consists of an external domain which binds the ligand, 
a transmembrane part and a cytoplasmatic part, which bears 
the characteristics of tyrosine kinase. The ErB2 receptor does 
not possess its own ligands, but it may undergo heterodi-
merisation with the remaining receptors, thus becoming 
activated. 
Clinical trials have shown symptomatic and asymptoma-
tic heart dysfunction in 4.7% of patients treated with trastu-
zumab only and in 27% of patients in whom trastuzumab is 
combined with anthracyclines. Risk factors of cardiotoxicity 
of trastuzumab include older age, previous treatment with 
anthracyclines and forms of heart injuries associated with 
concomitant diseases.
Under physiological conditions, activation of the Erb2 
receptor within the heart is responsible for maintaining the 
correct structure and function of the myocardium. Binding 
with type 1 neuregulin (NRG1) activates the enzymatic pa-
thway which determines the response to oxidative stress 
and initiates repairing mechanisms through the ERK and 
AKT routes. PI3K activation catalyses phosphorylation of 
the PK domain of AKT kinase, thus in turn initiating cellular 
mechanisms responsible for the growth and survival of 
myocytes. PI3K activation is possible through active RAS 
proteins. Additionally, NRG1 inhibition indirectly blocks the 
SRc and Fak routes, which exacerbates left ventricular dys-
function. Studies conducted on murine neonates in which 
the over-expression of antiapoptotic Bcl-XL cardiomyocyte 
protein has been genetically induced, has supported its 
protective role for developing dilation and hypertrophy of 
the myocardium on reaching adulthood [32–34]. 
It is important, that the type of cardiotoxicity induced 
by trastuzumab is classified as type II and reversible. The 
decrease in the ejection fraction is, in most cases, asympto-
matic [6, 7, 32]. The HERA study has shown an asymptomatic 
decrease of the ejection fraction in 7% of patients, while 
symptomatic patients accounted for 1.7%. In the NSABP 
B1 study, this ratio was 14.2% and 4.7%, respectively (these 
differences arose mainly from qualification criteria and from 
methods used to assess cardiotoxicity) [35].
Ewer conducted a study in order to assess the clinical 
course of cardiotoxicity over a period of four years from the 
termination of anthracyclines treatment and under trastu-
zumab follow-up treatment [36]. 
The ejection fraction increased in 56% of patients after 
the withdrawal of trastuzumab and in 66% of cases treat-
ment was recommenced. The median time for the ejection 
fraction to increase was 1.5 months. Only 12% of subjects 
developed left ventricle dysfunction.
A humanised monoclonal antibody which blocks the 
external subdomain of the ErbB2 receptor through inhi-
biting the dimerisation of the receptor, especially with the 
ErbB3 receptor, is pertuzumab which is yet another antibody 
which may be potentially useful for treating patients both 
with early and advanced breast cancer. Hitherto, studies 
have shown that for pertuzumab, cardiac failure is relatively 
rare and does not exceed a 1.2% rate in subjects. This diffe-
rence is likely because of a different mechanism of action on 
the ErbB2 receptor. Within the cardiomyocyte, an important 
part of its protective mechanism is activating the ErbB2/ 
/ErbB4 dimer through NRG1 ligand binding to ErbB4. Pertu-
zumab inhibits the dimerisation process through inhibiting 
the ligand binding to the ErbB3 receptor [7].
39
When assessing the potential risk of developing car-
diotoxicity (including heart failure associated with target 
therapy), one must always remember the different mechani-
sms of the two different molecular groups, that is the mAbs 
antibodies and the small molecules. Evidence for this has 
been provided by Spector et al, who has shown the possi-
ble protective function of lapatinib on the cardiomyocyte, 
which acts through the activation of a cardioprotective 
AMP-dependent kinase [37].
Published results of cardiovascular complication rates 
from randomised trials may actually show significantly dif-
ferent outcomes. 
Populations qualified for treatment under pre-set and 
under ‘normal’ conditions vary significantly according to 
their cardiac status. A study by Tarantini shows that in 160 
patients aged over 60 years, 32% had serious concomitant 
cardiovascular diseases. This is significantly more than in 
trial populations; the N-31 trial, the N9831 and the HEART 
of approximately 16% rates. Symptomatic cardiac failure 
was observed in 6% and in 2% before the age of 60. Trastu-
zumab was stopped in 10% of patients aged over 60 years 
and in 4% of patients below 60 years, whilst treatment was 
recommenced in 44% of patients over 60 years and in 58% 
of patients aged below 60.
Whenever ABL inhibitors are used for treatment, it is 
assumed that left ventricular dysfunction for imatinib does 
not exceed 1%. During electron microscopy investigations, 
myocyte necrosis was found; probably associated with 
apoptosis. It is likely that this mechanisms is similar to that 
observed in CML cells. Imatinib inhibits cellular processes 
responsible for deactivating oxidative stress, which become 
activated by the listed kinases.
Dilative cardiomyopathy was found in 4% patients tre-
ated with dasatinib and was caused by blocking the ABL/ 
/SRC route within the heart [12].
Cardiac incidents (including myocardial infarction, car-
diac failure sudden cardiac death) are found in around 11% 
of GIST patients resistant to imatinib. In a retrospective study 
on a group of 224 patients, heart failure developed in 2.7% 
of patients and the median time to developing symptoms 
of cardiac failure was 22 days from the onset of sunitinib 
therapy, which supports the concept of the cumulative 
effect of sunitinib cardiotoxicity and its dependence on 
the duration of treatment [39]. It is estimated that cardiac 
failure, defined as a decrease in ejection fraction by over 
15%, occurs in about 9–18% of patients. In a clinical trial on 
75 patients, Chu had shown a below 50% fall of the ejection 
fraction in 20% of patients; 8% of subjects having had symp-
toms of NYHA III or IV cardiac failure [13]. In 4.6% of patients 
studied by Telli, systolic dysfunction was seen; defined as 
a fall in ejection fraction below 20% of the initial value. The 
listed risk factors included previous cardiac disease (cardiac 
failure, angina) and low BMI values [40].
An interesting meta-analysis was prepared based upon 
the results published in the Medline database between 
January 1996 and February 2011. Subjects consisted of 
almost 7000 patients treated with sunitinib. In 45 cases, 
cardiac dysfunction was observed (in 1.5% of patients this 
was found to be significant), but no differences in the frequ-
ency of cardiac incidents were seen; neither depending on 
the type of disease nor on cardiac observation (renal cancer 
as compared to other malignancies; cardiac observation 
vs none) [41].
Pathologic features observed by electron microscopy 
showed cardiomyocyte hypertrophy with damaged mito-
chondria (oedema, altered structure, increased permeabi-
lity of the mitochondrial membrane without necrosis nor 
intracellular tissue hypertrophy). Murine studies have only 
revealed cardiomyocyte necrosis in cases of arterial pressure 
stress induced by phenylephrine [20].
Numerous published observations from a significant 
number of clinical trials show that cardiac toxicity is usually 
reversible and disappears after treatment withdrawal in the 
majority of patients. However in some patients they may be 
severe, even resulting in death [17].
Summary
The use of modern diagnostic and therapeutic modali-
ties has both significantly increased the number of complete 
recoveries and the survival of cancer patients. Nevertheless, 
the problem of treatment side-effects (incl. cardiovascular) 
remains a critical issue in oncology. This paper presents the 
most important issues of cardiotoxicity particularly regar-
ding everyday practice of the oncologist. It also points out 
areas in which direct collaboration between the oncologist 
and the cardiologist may be necessary in order to provide 
optimal therapy for dealing with cardiac complications ari-
sing from oncological treatment.
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